Medexus Pharmaceuticals Inc (OTCMKTS:PDDPF) is a Canadian specialty pharmaceutical company focused on acquiring, developing and commercializing innovative healthcare products primarily for the Canadian market. Headquartered in Vancouver, British Columbia, the company targets therapeutic areas including immunology, hematology, oncology and supportive care with its portfolio of both branded and generic pharmaceuticals.
Among its key offerings, Medexus markets Cutaquig, a subcutaneous immunoglobulin therapy for patients with primary immunodeficiency, and CIVATM (interferon gamma-1b) for the treatment of chronic granulomatous disease. The company has expanded its portfolio through strategic licensing agreements and acquisitions, enabling it to address niche and high-need patient populations. Medexus also holds rights to several specialty products under development for rare and orphan diseases.
While its core operations are based in Canada, Medexus has extended its reach into the United States through its wholly-owned subsidiary Silver Therapeutics. This U.S. arm focuses on specialty dermatology and women’s health products, leveraging Medexus’s commercial expertise to introduce established therapies to new markets. Distribution in Canada is supported by partnerships with national wholesalers and regional distributors, ensuring broad access to its treatments.
Led by President and Chief Executive Officer Ian Mortimer, Medexus benefits from a management team with deep experience in pharmaceutical R&D, regulatory affairs and commercial operations. The company continues to explore licensing and acquisition opportunities to grow its product pipeline, with a strategic emphasis on therapies that address unmet medical needs and offer clear benefits for patients and healthcare systems.
AI Generated. May Contain Errors.
